ASLAN Pharmaceuticals Ownership 2024 | Who Owns ASLAN Pharmaceuticals Now?
Institutional Ownership
3.46%
Insider Ownership
0.14%
Retail Ownership
96.41%
Institutional Holders
1.00
ASLAN Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VIVO CAPITAL, LLC | - | - | - | -568,182 | -100.00% | - | Dec 31, 2023 |
ASLAN Pharmaceuticals's largest institutional shareholder is VIVO CAPITAL, LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VIVO CAPITAL, LLC | - | - | - | -568,182 | -100.00% | - | Dec 31, 2023 |
The largest ASLAN Pharmaceuticals shareholder by % of total assets is VIVO CAPITAL, LLC. The company owns 0.00 shares of ASLAN Pharmaceuticals (ASLN), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VIVO CAPITAL, LLC | - | - | - | -568,182 | -100.00% | - | Dec 31, 2023 |
As of Dec 31 2023, ASLAN Pharmaceuticals's largest institutional buyer is VIVO CAPITAL, LLC. The company purchased -0.57M stocks of ASLN, valued at -.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VIVO CAPITAL, LLC | - | - | - | -568,182 | -100.00% | - | Dec 31, 2023 |
As of Dec 31 2023, ASLAN Pharmaceuticals's biggest institutional seller is VIVO CAPITAL, LLC. The company sold -0.57M shares of ASLN, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VIVO CAPITAL, LLC | - | - | - | -568,182 | -100.00% | - | Dec 31, 2023 |
ASLAN Pharmaceuticals's largest sold out institutional shareholder by shares sold is VIVO CAPITAL, LLC, sold -0.57M shares, valued at -, as of undefined.
ASLAN Pharmaceuticals Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| SPDR INDEX SHARES FUNDS | 0.00% | 42,486 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 39,841 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 7,968 | - | - | Feb 29, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.00% | 80 | - | - | Feb 29, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 185 | - | - | Mar 31, 2024 |
ASLAN Pharmaceuticals's largest mutual fund holder by % of total assets is "SPDR INDEX SHARES FUNDS", owning 42.49K shares, compromising 0.00% of its total assets.
ASLAN Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Sep, 23 | 1 | - |
| 30 Jun, 23 | 1 | - |
| 31 Mar, 23 | 1 | -96.00% |
| 31 Dec, 22 | 25 | -7.41% |
| 30 Sep, 22 | 27 | 3.85% |
| 30 Jun, 22 | 26 | -16.13% |
| 31 Mar, 22 | 31 | -6.06% |
| 31 Dec, 21 | 33 | -19.51% |
| 30 Sep, 21 | 41 | 32.26% |
| 30 Jun, 21 | 31 | -24.39% |
| 31 Mar, 21 | 41 | 241.67% |
| 31 Dec, 20 | 12 | 71.43% |
| 30 Sep, 20 | 7 | -22.22% |
| 30 Jun, 20 | 9 | -10.00% |
| 31 Mar, 20 | 10 | -28.57% |
| 31 Dec, 19 | 14 | 133.33% |
| 30 Sep, 19 | 6 | -14.29% |
| 30 Jun, 19 | 7 | -12.50% |
| 31 Mar, 19 | 8 | - |
| 31 Dec, 18 | 8 | 14.29% |
| 30 Sep, 18 | 7 | - |
| 30 Jun, 18 | 7 | - |
As of 30 Sep 23, 1 institutions are holding ASLAN Pharmaceuticals's shares, representing an increase of 0.00% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Sep, 23 | 568,182 | -80.00% |
| 30 Jun, 23 | 2,840,908 | -0.00% |
| 31 Mar, 23 | 2,840,909 | -84.55% |
| 31 Dec, 22 | 18,390,639 | -16.53% |
| 30 Sep, 22 | 22,033,115 | -5.88% |
| 30 Jun, 22 | 23,410,500 | -8.01% |
| 31 Mar, 22 | 25,448,049 | -5.60% |
| 31 Dec, 21 | 26,957,617 | 7.01% |
| 30 Sep, 21 | 25,192,227 | -9.60% |
| 30 Jun, 21 | 27,867,467 | 0.88% |
| 31 Mar, 21 | 27,623,099 | 339.10% |
| 31 Dec, 20 | 6,290,809 | 84.55% |
| 30 Sep, 20 | 3,408,753 | -2.30% |
| 30 Jun, 20 | 3,489,001 | 3.69% |
| 31 Mar, 20 | 3,364,894 | 2.14% |
| 31 Dec, 19 | 3,294,340 | 44.37% |
| 30 Sep, 19 | 2,281,944 | -0.51% |
| 30 Jun, 19 | 2,293,688 | -8.61% |
| 31 Mar, 19 | 2,509,668 | -16.28% |
| 31 Dec, 18 | 2,997,835 | -13.84% |
| 30 Sep, 18 | 3,479,535 | -0.55% |
| 30 Jun, 18 | 3,498,856 | - |
ASLAN Pharmaceuticals (ASLN) has 568.18K shares outstanding as of 30 Sep 23, down -80.00% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Sep, 23 | 3.46% | 0.94% |
| 30 Jun, 23 | 19.16% | 5.22% |
| 31 Mar, 23 | 19.16% | 2.76% |
| 31 Dec, 22 | 26.37% | 2.64% |
| 30 Sep, 22 | 31.59% | 2.80% |
| 30 Jun, 22 | 33.57% | 2.52% |
| 31 Mar, 22 | 36.49% | 2.13% |
| 31 Dec, 21 | 41.39% | 2.77% |
| 30 Sep, 21 | 38.68% | 0.74% |
| 30 Jun, 21 | 72.49% | 1.40% |
| 31 Mar, 21 | 71.85% | 26.83% |
| 31 Dec, 20 | 16.36% | 20.81% |
| 30 Sep, 20 | 8.87% | 7.68% |
| 30 Jun, 20 | 10.74% | 10.01% |
| 31 Mar, 20 | 10.36% | 10.07% |
| 31 Dec, 19 | 10.14% | 20.55% |
| 30 Sep, 19 | 7.03% | 14.09% |
| 30 Jun, 19 | 7.06% | 11.83% |
| 31 Mar, 19 | 7.73% | 9.07% |
| 31 Dec, 18 | 9.23% | 8.04% |
| 30 Sep, 18 | 10.71% | 9.23% |
| 30 Jun, 18 | 10.77% | - |
As of 30 Sep 23, ASLAN Pharmaceuticals is held by 3.46% institutional shareholders, representing a 0.94% growth compared to 30 Jun 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Sep, 23 | - | - |
| 30 Jun, 23 | - | - |
| 31 Mar, 23 | - | -100.00% |
| 31 Dec, 22 | 7 | -12.50% |
| 30 Sep, 22 | 8 | 14.29% |
| 30 Jun, 22 | 7 | -46.15% |
| 31 Mar, 22 | 13 | - |
| 31 Dec, 21 | 13 | -40.91% |
| 30 Sep, 21 | 22 | 57.14% |
| 30 Jun, 21 | 14 | -58.82% |
| 31 Mar, 21 | 34 | 183.33% |
| 31 Dec, 20 | 12 | 500.00% |
| 30 Sep, 20 | 2 | -33.33% |
| 30 Jun, 20 | 3 | -40.00% |
| 31 Mar, 20 | 5 | -54.55% |
| 31 Dec, 19 | 11 | 266.67% |
| 30 Sep, 19 | 3 | 50.00% |
| 30 Jun, 19 | 2 | -33.33% |
| 31 Mar, 19 | 3 | 50.00% |
| 31 Dec, 18 | 2 | - |
| 30 Sep, 18 | - | -100.00% |
| 30 Jun, 18 | 7 | - |
- institutional shareholders have increased their position in ASLN stock as of 30 Sep 23 compared to - in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Sep, 23 | 1 | - |
| 30 Jun, 23 | 1 | - |
| 31 Mar, 23 | - | -100.00% |
| 31 Dec, 22 | 8 | -20.00% |
| 30 Sep, 22 | 10 | 100.00% |
| 30 Jun, 22 | 5 | -37.50% |
| 31 Mar, 22 | 8 | - |
| 31 Dec, 21 | 8 | - |
| 30 Sep, 21 | 8 | - |
| 30 Jun, 21 | 8 | 60.00% |
| 31 Mar, 21 | 5 | - |
| 31 Dec, 20 | - | -100.00% |
| 30 Sep, 20 | 2 | - |
| 30 Jun, 20 | 2 | -33.33% |
| 31 Mar, 20 | 3 | 200.00% |
| 31 Dec, 19 | 1 | - |
| 30 Sep, 19 | 1 | -75.00% |
| 30 Jun, 19 | 4 | - |
| 31 Mar, 19 | 4 | 33.33% |
| 31 Dec, 18 | 3 | - |
| 30 Sep, 18 | 3 | - |
| 30 Jun, 18 | - | - |
1 institutional shareholders have reduced their position in ASLN stock as of 30 Sep 23 compared to 1 in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Sep, 23 | 1 | - | 568,182 | -80.00% | 3.46% | 0.94% | - | - | 1 | - |
| 30 Jun, 23 | 1 | - | 2,840,908 | -0.00% | 19.16% | 5.22% | - | - | 1 | - |
| 31 Mar, 23 | 1 | -96.00% | 2,840,909 | -84.55% | 19.16% | 2.76% | - | -100.00% | - | -100.00% |
| 31 Dec, 22 | 25 | -7.41% | 18,390,639 | -16.53% | 26.37% | 2.64% | 7 | -12.50% | 8 | -20.00% |
| 30 Sep, 22 | 27 | 3.85% | 22,033,115 | -5.88% | 31.59% | 2.80% | 8 | 14.29% | 10 | 100.00% |
| 30 Jun, 22 | 26 | -16.13% | 23,410,500 | -8.01% | 33.57% | 2.52% | 7 | -46.15% | 5 | -37.50% |
| 31 Mar, 22 | 31 | -6.06% | 25,448,049 | -5.60% | 36.49% | 2.13% | 13 | - | 8 | - |
| 31 Dec, 21 | 33 | -19.51% | 26,957,617 | 7.01% | 41.39% | 2.77% | 13 | -40.91% | 8 | - |
| 30 Sep, 21 | 41 | 32.26% | 25,192,227 | -9.60% | 38.68% | 0.74% | 22 | 57.14% | 8 | - |
| 30 Jun, 21 | 31 | -24.39% | 27,867,467 | 0.88% | 72.49% | 1.40% | 14 | -58.82% | 8 | 60.00% |
| 31 Mar, 21 | 41 | 241.67% | 27,623,099 | 339.10% | 71.85% | 26.83% | 34 | 183.33% | 5 | - |
| 31 Dec, 20 | 12 | 71.43% | 6,290,809 | 84.55% | 16.36% | 20.81% | 12 | 500.00% | - | -100.00% |
| 30 Sep, 20 | 7 | -22.22% | 3,408,753 | -2.30% | 8.87% | 7.68% | 2 | -33.33% | 2 | - |
| 30 Jun, 20 | 9 | -10.00% | 3,489,001 | 3.69% | 10.74% | 10.01% | 3 | -40.00% | 2 | -33.33% |
| 31 Mar, 20 | 10 | -28.57% | 3,364,894 | 2.14% | 10.36% | 10.07% | 5 | -54.55% | 3 | 200.00% |
| 31 Dec, 19 | 14 | 133.33% | 3,294,340 | 44.37% | 10.14% | 20.55% | 11 | 266.67% | 1 | - |
| 30 Sep, 19 | 6 | -14.29% | 2,281,944 | -0.51% | 7.03% | 14.09% | 3 | 50.00% | 1 | -75.00% |
| 30 Jun, 19 | 7 | -12.50% | 2,293,688 | -8.61% | 7.06% | 11.83% | 2 | -33.33% | 4 | - |
| 31 Mar, 19 | 8 | - | 2,509,668 | -16.28% | 7.73% | 9.07% | 3 | 50.00% | 4 | 33.33% |
| 31 Dec, 18 | 8 | 14.29% | 2,997,835 | -13.84% | 9.23% | 8.04% | 2 | - | 3 | - |
| 30 Sep, 18 | 7 | - | 3,479,535 | -0.55% | 10.71% | 9.23% | - | -100.00% | 3 | - |
| 30 Jun, 18 | 7 | - | 3,498,856 | - | 10.77% | - | 7 | - | - | - |
ASLAN Pharmaceuticals Peer Ownership
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| ACHL | Achilles Therapeutics plc |
| IVA | Inventiva S.A. |
| IOBT | IO Biotech, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| ERAS | Erasca, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| NLTX | Neurogene Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| TIL | Instil Bio, Inc. |
| CMPX | Compass Therapeutics, Inc. |
ASLN Ownership FAQ
Who Owns ASLAN Pharmaceuticals?
ASLAN Pharmaceuticals is owned by institutional shareholders (3.46%), insiders (0.14%), and public (96.41%). The largest institutional shareholder of ASLAN Pharmaceuticals is VIVO CAPITAL, LLC (0% of total shares) and the top mutual fund owner is SPDR INDEX SHARES FUNDS (0.00% of total shares).
Who are the major institutional shareholders of ASLAN Pharmaceuticals?
ASLAN Pharmaceuticals's major institutional shareholders are VIVO CAPITAL, LLC. The top five shareholders own together 0% of the company's share outstanding.
How many ASLAN Pharmaceuticals shareholders are there?
As of Sep 2023, there are 1 institutional shareholders of ASLAN Pharmaceuticals.
What percentage of ASLAN Pharmaceuticals is owned by VIVO CAPITAL, LLC?
VIVO CAPITAL, LLC owns 0 shares of ASLAN Pharmaceuticals, representing 0% of the company's total shares outstanding, valued at $0 (as of Dec 2023).